PRTC

MKT CAP:$413M

PureTech Health plc

Market Cap

$413M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$18.04+$1.40 (+8.41%)

Apr 22, 2026

Company Details

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsycho...

CEO

Robert Lyne

IPO Date

Nov 16, 2020

Website

www.puretechhealth.com

Key Metrics TTM

Revenue

$14M

-51.3% YoY

Net Income

-$134M

EPS (Diluted)

-$4.25

Free Cash Flow

-$292M

Revenue / Share

$0.60

Gross Margin

-605.1%

Operating Margin

-2041.2%

Net Margin

-940.5%

FCF Margin

-2043.0%

P/S

28.9x

P/E

—

Earnings Reports

Q3 2025

Apr 30, 2026

PENDING

Q2 2025

Aug 28, 2025

$2M+542.7%EPS -$1.90

Q2 2024

Jun 28, 2024

$288.0K-90.9%EPS -$1.50

FY 2023

Apr 25, 2024

$3MEPS -$2.40

Q2 2023

Aug 29, 2023

$3M-55.2%EPS -$0.45

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 16	$4M	-$37M	-$39M
Q2 17	$665.0K	-$34M	-$57M
Q4 17	$2M	-$34M	-$58M
Q2 18	$5M	-$28M	-$52M
Q4 18	$16M	-$28M	-$52M
Q2 19	$4M	-$18M	-$70M
Q4 19	$5M	-$60M	-$66M
Q2 20	$7M	-$31M	-$53M
Q4 20	$5M	-$14M	-$66M
Q2 21	$6M	-$18M	-$68M
Q4 21	$12M	-$75M	-$83M
Q2 22	$7M	-$35M	-$101M
Q4 22	$9M	-$25M	-$101M
Q2 23	$3M	$89.0K	-$76M
Q2 24	$288.0K	-$39M	-$66M
Q2 25	$2M	-$23M	-$48M

Valuation

Quarter	P/S	P/E
Q4 16	67.7x	—
Q2 17	185.3x	—
Q4 17	157.9x	—
Q2 18	94.0x	2981.1x
Q4 18	47.2x	—
Q2 19	40.7x	20.6x
Q4 19	35.9x	2.9x
Q2 20	33.9x	2.1x
Q4 20	71.6x	3.6x
Q2 21	60.1x	4.2x
Q4 21	35.9x	—
Q2 22	20.8x	—
Q4 22	26.4x	—
Q2 23	26.1x	—
Q2 24	33.6x	—
Q2 25	32.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 16	-$29M	-$31M
Q2 17	-$45M	-$46M
Q4 17	-$44M	-$45M
Q2 18	-$44M	-$46M
Q4 18	-$29M	-$31M
Q2 19	-$35M	-$51M
Q4 19	-$64M	-$62M
Q2 20	-$56M	-$58M
Q4 20	-$73M	-$77M
Q2 21	-$65M	-$68M
Q4 21	-$94M	-$97M
Q2 22	-$87M	-$89M
Q4 22	-$100M	-$101M
Q2 23	-$65M	-$65M
Q2 24	-$80M	-$80M
Q2 25	-$46M	-$46M

Capital Expenditures

Quarter	CapEx
Q4 16	$1M
Q2 17	$1M
Q4 17	$984.0K
Q2 18	$2M
Q4 18	$2M
Q2 19	$15M
Q4 19	$2M
Q2 20	$2M
Q4 20	$3M
Q2 21	$3M
Q4 21	$3M
Q2 22	$2M
Q4 22	$635.5K
Q2 23	$70.0K
Q2 24	$0
Q2 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 16	+287.1%	+220.0%
Q2 17	-93.9%	+153.3%
Q4 17	+122.9%	+82.8%
Q2 18	+1948.1%	+64.7%
Q4 18	+276.6%	+54.9%
Q2 19	+559.7%	+30.5%
Q4 19	+193.7%	+18.9%
Q2 20	+37.5%	+4.0%
Q4 20	-69.3%	+4.4%
Q2 21	+33.0%	-1.1%
Q4 21	+112.3%	+32.4%
Q2 22	+2.7%	+81.5%
Q4 22	+86.3%	+56.8%
Q2 23	-46.0%	+7.3%
Q2 24	-97.5%	-29.5%
Q2 25	-73.7%	-54.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 16	$5M	116.6%
Q2 17	$7M	1071.6%
Q4 17	$5M	252.6%
Q2 18	$4M	75.4%
Q4 18	$9M	56.3%
Q2 19	$3M	72.8%
Q4 19	$4M	73.5%
Q2 20	$3M	38.0%
Q4 20	$3M	57.0%
Q2 21	$3M	48.3%
Q4 21	$4M	35.6%
Q2 22	$2M	25.3%
Q4 22	$6M	61.9%
Q2 23	$628.0K	19.9%
Q2 24	$5M	1613.9%
Q2 25	$5M	255.7%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 16	$26M	$16M	$1M
Q2 17	$35M	$22M	—
Q4 17	$36M	$23M	$1M
Q2 18	$33M	$24M	—
Q4 18	$44M	$21M	$3M
Q2 19	$45M	$15M	$12M
Q4 19	$41M	$15M	$12M
Q2 20	$77M	$21M	$17M
Q4 20	$43M	$14M	$10M
Q2 21	$48M	$13M	$9M
Q4 21	$63M	$16M	$12M
Q2 22	$85M	$12M	$8M
Q4 22	$71M	$19M	$16M
Q2 23	$53M	$13M	$10M
Q2 24	$39M	$28M	—
Q2 25	$25M	$25M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 17	$73M	$116M	$189M
Q2 18	$90M	$110M	$200M
Q4 18	$117M	$134M	$251M
Q2 19	$132M	$72M	$204M
Q4 19	$132M	$30M	$162M
Q2 20	$340M	$2M	$342M
Q4 20	$404M	$0	$404M
Q2 21	$440M	$2M	$442M
Q4 21	$466M	$0	$466M
Q2 22	$366M	$2M	$368M
Q4 22	$150M	$200M	$350M
Q2 23	$351M	$2M	$352M
Q4 23	$191M	$136M	$327M
Q2 24	$308M	$192M	$500M
Q4 24	$281M	$87M	$367M
Q2 25	$261M	$59M	$320M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 16	23M	+1.7%	+128.6%
Q2 17	24M	+1.7%	+61.2%
Q4 17	24M	+2.9%	+8.0%
Q2 18	26M	+9.3%	+16.4%
Q4 18	28M	+6.8%	+22.2%
Q2 19	29M	+1.0%	+21.3%
Q4 19	30M	+4.3%	+22.9%
Q2 20	29M	-1.4%	+10.9%
Q4 20	29M	-2.7%	+1.0%
Q2 21	29M	+0.1%	+0.1%
Q4 21	29M	+0.4%	-3.6%
Q2 22	29M	+0.2%	-2.0%
Q4 22	28M	-2.1%	-1.4%
Q2 23	28M	-1.2%	-2.7%
Q2 24	27M	-3.1%	-6.1%
Q2 25	24M	-11.0%	-16.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 16	—	—
Q2 17	—	—
Q4 17	—	—
Q2 18	—	—
Q4 18	—	—
Q2 19	—	—
Q4 19	—	—
Q2 20	—	—
Q4 20	$24	200K
Q2 21	$29	200K
Q4 21	$58	200K
Q2 22	$35	200K
Q4 22	$45	200K
Q2 23	$16	200K
Q2 24	$1	200K
Q2 25	$9	200K

Revenue / Employee